Epidemiological and Clinical Translational Studies Post Genome-Wide Association

项目3：全基因组关联后的流行病学和临床转化研究（GWAS） 项目负责人：Rosalind Eeles 项目摘要： 项目3的主要重点是建立一个由临床科学家、流行病学家、遗传学家和生物统计学家组成的跨学科合作网络，重点是从“台侧”研究过渡到“床侧”护理。CEC（临床ELLIPSE联盟）将协调来自现有联盟的遗传、临床和环境数据，超过35，000例前列腺癌病例，以评估基因、基因和基因环境对前列腺癌风险的影响，包括侵袭性疾病、复发和死亡率。高度整合的ELLIPSE项目将通过与项目1（确定新的遗传候选物）和项目2（提供功能的生物学见解）密切合作，促进最新的遗传评估。将对遗传和环境相互作用的评估进行评价，以纳入风险评分，并可能为项目1和2提供方向性投入。将在欧洲、非洲裔美国人和日本人群中评估所有风险评价。最后，这个初始阶段将为开发有用和强大的前列腺癌风险预测模型提供必要的指导，包括筛查，结果和治疗效果。这些风险预测模型可以通过为临床医生提供必要的工具来改善临床决策，从而对公共卫生产生直接影响。

Project 3: Epidemiological and Clinical Translational Studies Post Genome-Wide Association (GWAS) Project Leader: Rosalind Eeles Project Summary: The main focus of Project 3 is establishing a transdisciplinary collaborative network comprised of clinical scientists, epidemiologists, geneticists, and biostatisticians focusing on the transition from 'bench-side' research to 'bed-side' care. The CEC (Clinical ELLIPSE Consortium) will harmonize genetic, clinical, and environmental data from existing consortia, with over 35,000 prostate cancer cases, to evaluate gene, genegene, and gene-environmental effects on prostate cancer risk, including aggressive disease, recurrence, and mortality. The highly integrated ELLIPSE projects will facilitate the most up to date genetic evaluation by working closely with Project 1, identifying novel genetic candidates, and Project 2, providing biological insights on function. The assessment of genetic and environmental interactions will be evaluated for inclusion into a risk score as well as potentially providing directional input for Projects 1 and 2. All risk evaluations will be assessed in European, African American, and Japanese populations. Finally, this initial stage will provide the necessary guidance in developing useful and powerful risk prediction models for prostate cancer risk, including screening, outcome and treatment effects. These risk prediction models may have an immediate public health impact by providing clinicians with the necessary tools to improve clinical-decision making.